Norursodeoxycholic acid

Unassigned

New Medicines

Norurso · Primary sclerosing cholangitis in patients aged 16 years and older

Information

Norurso
New molecular entity
Dr Falk
Dr Falk

Development and Regulatory status

None
Phase III Clinical Trials
None
Yes

Category

Homologue of ursodeoxycholic acid, thought to repeatedly be secreted by the liver cells, partially re-absorbed by the bile duct cells, and taken up by the liver cells again. Repetition of this cycle prevents build-up of bile acids.
PSC is a rare disease with a prevalence of 0.2-16 per 100,000. PSC commonly affects males with a median age at diagnosis of 35 years. PSC accounts for 10% of all UK liver transplants [1].
Primary sclerosing cholangitis in patients aged 16 years and older
Oral